REG - Oxford Biomedica PLC - Block listing Interim Review

Oxford BioMedicaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nRSA0771Pa&default-theme=true

RNS Number : 0771P  Oxford Biomedica PLC  01 July 2025

 Name of applicant:                                                                OXFORD BIOMEDICA PLC
 Name of scheme:                                                                   2015 Employee Share Option Scheme
 Period of return:                        From:                                    1 January 2025  To:           30 June 2025
 Balance of unallotted securities under scheme(s) from previous return:            283,522
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         2,686
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        280,836

 

 

 Name of applicant:                                                                OXFORD BIOMEDICA PLC
 Name of scheme:                                                                   2015 and 2024 Long Term Incentive Plan
 Period of return:                        From:                                    1 January 2025  To:            30 June 2025
 Balance of unallotted securities under scheme(s) from previous return:            560,726
 Plus:  The amount by which the block scheme(s) has been increased since the       550,000
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         120,497
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        990,229

 

 

 

 

 

 

 

 

 

 

 Name of applicant:                                                                OXFORD BIOMEDICA PLC
 Name of scheme:                                                                   2015 and 2024 Deferred Bonus Plan
 Period of return:                        From:                                    1 January 2025  To:           30 June 2025
 Balance of unallotted securities under scheme(s) from previous return:            375,061
 Plus:  The amount by which the block scheme(s) has been increased since the       200,000
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         52,612
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        522,449

 

 

 

 Name of applicant:                                                                OXFORD BIOMEDICA PLC
 Name of scheme:                                                                   Sharesave Scheme
 Period of return:                        From:                                    1 January 2025  To:      30 June 2025
 Balance of unallotted securities under scheme(s) from previous return:            339,040
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        339,040

 

 Name of contact:              Natalie Walter, Company Secretary
 Telephone number of contact:  01865 783000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRWPUPPQUPAGMU